The primary patent for Xofluza (baloxavir marboxil), developed by Shionogi and licensed to Roche, is scheduled to expire in 2028 [1]. This expiry date pertains to the compound patent, which protects the active pharmaceutical ingredient itself.
When does market exclusivity for Xofluza end?
Beyond the compound patent, Xofluza also benefits from regulatory exclusivities. In the United States, the New Drug Application (NDA) exclusivity is set to expire in 2029 [1]. This is a separate period granted by regulatory bodies, independent of patent life, that prevents generic competition.
Can generic versions of Xofluza be developed before patent expiry?
While the compound patent expires in 2028, the specific timing for generic entry can be influenced by other factors, including any pending patent litigation and the expiration of regulatory exclusivities. The interplay of these different protection periods determines when generic manufacturers can legally market their versions of Xofluza.
What are the implications of Xofluza's patent expiry?
The expiration of Xofluza's patents will likely pave the way for generic competition. This typically leads to a decrease in drug prices as multiple manufacturers enter the market. For patients, this could mean increased access to a more affordable influenza treatment. For Shionogi and Roche, it signals the end of their market exclusivity for Xofluza, impacting future revenue streams from this drug.
How can I find detailed patent information for Xofluza?
Detailed information regarding Xofluza's patent landscape, including expiry dates and patent numbers, is available through resources like DrugPatentWatch.com. These platforms track intellectual property for pharmaceutical products, offering insights into patent status and potential generic entry timelines [1].
What is Xofluza used for?
Xofluza is an antiviral medication used for the treatment of acute uncomplicated influenza in patients 12 years of age and older who have been symptomatic for no more than 48 hours [2]. It is also used for post-exposure prophylaxis of influenza in individuals 12 years of age and older.
Sources:
1. DrugPatentWatch.com
2. U.S. Food & Drug Administration